| scholarly article | Q13442814 |
| P50 | author | Giampaolo Tortora | Q38544270 |
| Emilio Bria | Q46978152 | ||
| Roberto Ferrara | Q58327701 | ||
| Laura Mezquita | Q59548589 | ||
| P2093 | author name string | Virginie Westeel | |
| Julien Mazieres | |||
| Benjamin Besse | |||
| Jean-Charles Soria | |||
| Sylvestre Le Moulec | |||
| Serge Koscielny | |||
| David Planchard | |||
| Julien Adam | |||
| Stephane Champiat | |||
| Jordi Remon | |||
| Caroline Caramella | |||
| Laurent Tessonnier | |||
| Clarisse Audigier-Valette | |||
| Anas Gazzah | |||
| Solenn Brosseau | |||
| Boris Duchemann | |||
| Gerard Zalcman | |||
| Corentin Lefebvre | |||
| Charles Ferté | |||
| Jihene Lahmar | |||
| Laura Leroy | |||
| Marie-Eve Boucher | |||
| Matthieu Texier | |||
| Remi Veillon | |||
| P433 | issue | 11 | |
| P921 | main subject | non-small-cell lung carcinoma | Q3658562 |
| P304 | page(s) | 1543-1552 | |
| P577 | publication date | 2018-11-01 | |
| P1433 | published in | JAMA Oncology | Q22079683 |
| P1476 | title | Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy | |
| P478 | volume | 4 |
| Q90180941 | A Machine Learning Algorithm for Predicting Therapeutic Response to Anti-PD1 |
| Q95319497 | A guide to cancer immunotherapy: from T cell basic science to clinical practice |
| Q96341695 | Accelerating the Development of Personalized Cancer Immunotherapy by Integrating Molecular Patients' Profiles with Dynamic Mathematical Models |
| Q89497162 | Advances in clinical trials of targeted therapy and immunotherapy of lung cancer in 2018 |
| Q64267214 | Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patients' treatment |
| Q92309034 | Beyond DNA repair: the novel immunological potential of PARP inhibitors |
| Q94571288 | CD200 and CD200R1 are differentially expressed and have differential prognostic roles in non-small cell lung cancer |
| Q98163436 | Clinical characteristics of hyperprogressive disease in NSCLC after treatment with immune checkpoint inhibitor: a systematic review and meta-analysis |
| Q90751509 | Co-mutations of TP53 and KRAS serve as potential biomarkers for immune checkpoint blockade in squamous-cell non-small cell lung cancer: a case report |
| Q89623916 | Controversies in the management of hepatocellular carcinoma |
| Q93159917 | Cytology cell blocks from malignant pleural effusion are good candidates for PD-L1 detection in advanced NSCLC compared with matched histology samples |
| Q92759631 | Durable Clinical Response to Pyrotinib After Resistance to Prior Anti-HER2 Therapy for HER2-Positive Advanced Gastric Cancer: A Case Report |
| Q64081777 | Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential |
| Q89597173 | Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics |
| Q94591586 | Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer |
| Q103002135 | Empty mesoporous silica particles significantly delay disease progression and extend survival in a mouse model of ALS |
| Q90061437 | Factors related to rapid progression of non-small cell lung cancer in Chinese patients treated using single-agent immune checkpoint inhibitor treatment |
| Q64100514 | FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy |
| Q91712013 | How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors? |
| Q93188480 | How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy |
| Q91741324 | Hyperprogression after immunotherapy |
| Q89647127 | Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress? |
| Q89893280 | Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact? |
| Q97523279 | Hyperprogression of Liver Metastasis With Neoadjuvant Immunotherapy for Soft Tissue Sarcoma |
| Q89926719 | Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics |
| Q92446556 | Hyperprogression under Immunotherapy |
| Q91621515 | Hyperprogression with immunotherapy: Is it real? |
| Q100391098 | Hyperprogression: A novel response pattern under immunotherapy |
| Q92057809 | Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcinoma to Small-cell Carcinoma during Pembrolizumab Therapy |
| Q95818605 | Hyperprogressive Disease in an Advanced Stage Colon Cancer Patient on Pembrolizumab: A Case Report |
| Q93090758 | Hyperprogressive disease after treatment with pembrolizumab in lung adenocarcinoma: An autopsy case study |
| Q64939865 | Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer. |
| Q91621429 | Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities |
| Q64081254 | Hyperprogressive disease: a distinct effect of immunotherapy? |
| Q58561264 | Hyperprogressive disease: recognizing a novel pattern to improve patient management |
| Q93173548 | Identification of lung adenocarcinoma biomarkers based on bioinformatic analysis and human samples |
| Q92409210 | Imaging of tumour response to immunotherapy |
| Q64967509 | Immune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy. |
| Q90263373 | Immune checkpoint inhibitors in esophageal squamous cell carcinoma: progress and opportunities |
| Q91908238 | Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP) |
| Q89633233 | Immunotherapy by Immune Checkpoint Inhibitors and Nuclear Medicine Imaging: Current and Future Applications |
| Q89884047 | Immunotherapy for the Treatment of Breast Cancer: Emerging New Data |
| Q100737199 | Implications of metabolism-driven myeloid dysfunctions in cancer therapy |
| Q96175090 | Innovative highlights of clinical drug trial design |
| Q64073978 | Is the onset of adverse effects of immunotherapy always bad news for the patients…?-certainly not! |
| Q90093983 | Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement |
| Q91893359 | Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer |
| Q64081110 | Lymph node metastasis matters |
| Q89944086 | MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma |
| Q89856221 | Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature |
| Q95279024 | Mathematical prediction of clinical outcomes in advanced cancer patients treated with checkpoint inhibitor immunotherapy |
| Q92542049 | Maximum Somatic Allele Frequency in Combination With Blood-Based Tumor Mutational Burden to Predict the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer: A Pooled Analysis of the Randomized POPLAR and OAK Studies |
| Q90226731 | Molecular Modeling Studies on the Binding Mode of the PD-1/PD-L1 Complex Inhibitors |
| Q96950785 | Multicentre biomarker cohort study on the efficacy of nivolumab treatment for gastric cancer |
| Q91123974 | Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial |
| Q64939605 | Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date. |
| Q64081202 | PD1/PD-L1 inhibitor treatment for late stage non-small cell lung carcinoma, sometimes…does more harm than good! |
| Q92905895 | Pembrolizumab for all PD-L1-positive NSCLC |
| Q90428659 | Pembrolizumab monotherapy for PD-L1 ≥50% non-small cell lung cancer, undisputed first choice? |
| Q90220114 | Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy |
| Q92252194 | Personal response to immune checkpoint inhibitors of patients with advanced melanoma explained by a computational model of cellular immunity, tumor growth, and drug |
| Q89721751 | Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer |
| Q89537494 | Programmed Cell Death Protein-1 (PD-1)-Targeted Immunotherapy for Advanced Hepatocellular Carcinoma in Real World |
| Q93068290 | Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort |
| Q97518316 | Recommendations for detection, prioritization, and treatment of thoracic oncology patients during the COVID-19 pandemic: the THOCOoP cooperative group |
| Q92132117 | Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon? |
| Q92442311 | Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis prediction |
| Q91898387 | Substantial remission of prostate adenocarcinoma with dendritic cell therapy APCEDEN® in combination with chemotherapy |
| Q98463489 | Targeting PD-L1 in non-small cell lung cancer using CAR T cells |
| Q64081138 | The ABCs of preventing hyperprogressive disease after immunotherapy: awareness, biomarkers, and combination |
| Q92538988 | The Intriguing History of Cancer Immunotherapy |
| Q99582666 | The Lung Immune Prognostic Index (LIPI) stratifies prognostic groups in advanced non-small cell lung cancer (NSCLC) patients |
| Q94487070 | The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy |
| Q101574526 | The cutting-edge progress of immune-checkpoint blockade in lung cancer |
| Q92152031 | The good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy |
| Q91588661 | The great escape: How metastases of melanoma, and other carcinomas, avoid elimination |
| Q90088538 | The role of endobronchial ultrasound transbronchial needle aspiration for programmed death ligand 1 testing and next generation sequencing in advanced non-small cell lung cancer |
| Q90697039 | Therapeutic landscape of metastatic non-small-cell lung cancer in Canada in 2020 |
| Q100407600 | Treatment after progression in the era of immunotherapy |
| Q90244449 | Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy |
| Q92266207 | Tumor intrinsic immunity related proteins may be novel tumor suppressors in some types of cancer |
| Q92134989 | Tumour growth rate as a tool for response evaluation during PD-1 treatment for non-small cell lung cancer: a retrospective analysis |
| Q64998568 | Who will suffer from hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors. |
| Q92878364 | [Basis of Tumor Microenvironment Relevant to Immunotherapies for Brain Metastases of NSCLC] |
| Q99590522 | [Chinese Expert Consensus on Next Generation Sequencing Diagnosis for Non-small Cell Lung Cancer (2020 Edition)] |
| Q89862626 | [Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version)] |
| Q58579831 | [Tumor assessment in immune checkpoint inhibitor therapy : Tumor response, progression and pseudoprogression] |
Search more.